Prostate Specific Antigen
6
3
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
PROstate Cancer Risk Calculator for ACTionable Clinical Decision-making in Nigeria
Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy
Behavioral Economics Applications to Geriatrics Leveraging EHRs
A Cluster Package Intervention to Promote an Evidence-based Use of PSA-tests in General Practice
Changing of Prostate Specific Antigen Value in Patients With Covid-19